Safety note: Admin approval is an initial review, not a guarantee that every detail is correct. Check important or urgent claims with official sources and report anything inaccurate or unsafe.
Source and credit: Contributor's own report
Ceretas Moves Headquarters to Brisbane’s Edward Street - Brisbane, QLD
Smart summary
Medical technology company Ceretas has relocated its registered office and principal place of business to Brisbane’s Edward Street.
Medical technology company Ceretas Limited has announced the immediate relocation of its registered office and principal place of business to Edward Street in Brisbane’s CBD.
The company has moved its registered office to Level 4, 348 Edward Street, Brisbane, Queensland, with the change taking effect on 14 August 2026. The announcement was made as part of a formal company update.
Ceretas is a clinical-stage medical technology company developing a portable, non-invasive therapeutic ultrasound platform. Its technology is being developed for potential applications involving Alzheimer's disease and other neurological conditions.
The company says its technology is based on research developed through more than a decade of work involving researchers at The University of Queensland and the Queensland Brain Institute.
The platform uses low-intensity focused ultrasound delivered through the skull. The technology is being investigated for its potential effects on brain activity and for opening the blood-brain barrier, which could potentially support future therapeutic approaches.
Research associated with the technology has already progressed into human clinical studies. A first-in-human Phase 1 study involving Alzheimer's patients was completed in 2024, with research findings subsequently published.
Ceretas is now preparing for further clinical development, including a planned Phase 2 study focused on Alzheimer's patients experiencing behavioural and psychological symptoms associated with dementia.
The company has also highlighted another Phase 2 study being independently funded through Queensland Health.
The relocation to Brisbane's CBD places the company's registered office closer to Queensland's growing medical research and technology ecosystem. Brisbane has a strong connection to biomedical research through universities, hospitals, research institutions and technology companies.
The move also reflects the company's continuing development as it progresses its therapeutic ultrasound platform toward further clinical testing.
For Brisbane, the announcement adds another medical-technology company to the city's growing technology and research community. The city's universities and research institutions have increasingly contributed to developments in biotechnology, medical devices and healthcare innovation.
The company has confirmed that its other contact information remains unchanged following the relocation.
CompanyTechnologyResearchBrisbaneQueensland
Medical technology company Ceretas Limited has announced the immediate relocation of its registered office and principal place of business to Edward Street in Brisbane’s CBD.
The company has moved its registered office to Level 4, 348 Edward Street, Brisbane, Queensland, with the change taking effect on 14 August 2026. The announcement was made as part of a formal company update.
Ceretas is a clinical-stage medical technology company developing a portable, non-invasive therapeutic ultrasound platform. Its technology is being developed for potential applications involving Alzheimer's disease and other neurological conditions.
The company says its technology is based on research developed through more than a decade of work involving researchers at The University of Queensland and the Queensland Brain Institute.
The platform uses low-intensity focused ultrasound delivered through the skull. The technology is being investigated for its potential effects on brain activity and for opening the blood-brain barrier, which could potentially support future therapeutic approaches.
Research associated with the technology has already progressed into human clinical studies. A first-in-human Phase 1 study involving Alzheimer's patients was completed in 2024, with research findings subsequently published.
Ceretas is now preparing for further clinical development, including a planned Phase 2 study focused on Alzheimer's patients experiencing behavioural and psychological symptoms associated with dementia.
The company has also highlighted another Phase 2 study being independently funded through Queensland Health.
The relocation to Brisbane's CBD places the company's registered office closer to Queensland's growing medical research and technology ecosystem. Brisbane has a strong connection to biomedical research through universities, hospitals, research institutions and technology companies.
The move also reflects the company's continuing development as it progresses its therapeutic ultrasound platform toward further clinical testing.
For Brisbane, the announcement adds another medical-technology company to the city's growing technology and research community. The city's universities and research institutions have increasingly contributed to developments in biotechnology, medical devices and healthcare innovation.
The company has confirmed that its other contact information remains unchanged following the relocation.
A Queensland mayor has asked police to investigate a parody Facebook page featuring AI-generated videos, saying the content crosses the line into bullying.
A failed attempt to ban data centres in Perth’s northern suburbs has renewed calls for the WA Government to provide clearer planning rules for the rapid...
A Queensland mayor has asked police to investigate a parody Facebook page featuring AI-generated videos, saying the content crosses the line into bullying.
A Queensland mayor has asked police to investigate a parody Facebook page featuring AI-generated videos, saying the content crosses the line into bullying.
